ARTICLE SUMMARY:
Executive Editor David Filmore lays out key policy areas to watch in 2021 and drills down to what industry should anticipate in the opening weeks of the Biden administration; Setting the stage for MDUFA V talks; The clock is ticking, loudly, on EU IVDR implementation; Epigenomics’ attempts to secure a NCD for its CRC test; CRA’s Life Sciences team on how best to use the NUB reimbursement pathway to bring innovative medical technology to the German market. These stories and more.
